Welcome to our dedicated page for Pulsenmore SEC filings (Ticker: PLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulsenmore's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulsenmore's regulatory disclosures and financial reporting.
Pulsenmore Ltd. director Itkin Hagai filed an initial insider ownership report on Form 3. This filing establishes his status as a director and subject to insider reporting rules but does not list any specific share or option holdings or report any transactions.
Pulsenmore Ltd. director Linda Messalem has filed an initial statement of beneficial ownership showing stock option holdings. She holds options to purchase Ordinary Shares with an exercise price of $44.04 per share, granted on August 10, 2021 under the company’s 2019 Amended Share Incentive Plan.
According to the footnotes, one option grant is fully vested and exercisable. For another reported grant, 20,508 options are already vested, and an additional 1,464 options vest on May 10, 2026 and 1,465 options vest on August 10, 2026. The options are held directly in her name, with certain awards registered in a trustee’s name to qualify for Israeli tax benefits.
Pulsenmore Ltd., a foreign private issuer based in Israel, has furnished an updated corporate presentation as part of a Form 6-K report. The presentation, dated March 18, 2026, was posted on the company’s website and is attached to the report as Exhibit 99.1.
Pulsenmore Ltd. is expanding its U.S. presence through a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice in Maryland. TLC Perinatal will integrate Pulsenmore’s Early Screening home ultrasound services into a hybrid care model that blends at-home scans, telehealth, and in-clinic visits.
The practice, led by Medical Director Dr. Richard (Richie) Broth and managing about 2,000 pregnancies annually across two Maryland locations, plans to use Pulsenmore’s technology to support remote monitoring while physicians retain clinical oversight. Pulsenmore views this agreement as evidence of growing U.S. interest in patient-centric prenatal technologies following its FDA clearance.
Pulsenmore Ltd. reported its first commercial engagement with a medical center in the United States for its home pregnancy ultrasound service. This follows recent FDA clearance for the company’s home-use pregnancy ultrasound product.
On January 29, 2026, Pulsenmore, through a subsidiary, signed a services agreement with the Center for Fetal Medicine & Women’s Ultrasound, a fetal medicine and women’s ultrasound center operating from two locations in the Los Angeles area. Under this agreement, the center will purchase Pulsenmore ES home ultrasound services so pregnant patients can be remotely monitored and reduce unnecessary in-clinic diagnostic visits, with a particular focus on high-risk pregnancies.
Pulsenmore Ltd. has expanded its relationship with Clalit Health Services through a new commercial agreement for the Pulsenmore FC at-home follicular monitoring device for women undergoing IVF and fertility preservation in Israel. Following a feasibility trial at Rabin Medical Center that met its protocol criteria, the parties agreed to an 18‑month pilot in which Pulsenmore will sell and market Pulsenmore FC directly to Clalit patients, supported by Beilinson NEXT, Beilinson Medical Center’s virtual hospital platform.
After the pilot, the engagement is set to continue for a five-year term, with Clalit committing to a minimum annual purchase of 2,000 Pulsenmore FC units and the agreement potentially valued at approximately $4.5 million over those five years. Units sold directly by Pulsenmore to Clalit’s patients will count toward the annual minimum, and Clalit may return up to 1,000 units per year and sell units directly to its patients. The companies aim to offer at-home scans with real-time guidance and specialist oversight to reduce repeated in-clinic ultrasound visits during fertility treatment.
Pulsenmore Ltd. filed a report describing that its shares will begin trading on the Nasdaq Capital Market, while continuing to trade on the Tel Aviv Stock Exchange. The company develops home-use ultrasound and telehealth technology that lets physicians supervise prenatal monitoring outside traditional clinics, using proprietary hardware, secure cloud image transmission, and clinical review workflows.
Pulsenmore highlights that it has FDA authorization for its home-use prenatal ultrasound system and describes this as the first and only FDA-authorized home-use prenatal ultrasound system. Management views the Nasdaq listing as a transformative step that may increase visibility and liquidity and help attract a broader, global investor base aligned with its maternal-health focused growth strategy.